Orlando, FL - Intensive lipid-lowering treatment with atorvastatin (Lipitor ®, Pfizer) 80 mg daily completely halted the progression of atherosclerosis, whereas a moderate lipid-lowering regimen of ...

Another trend in the antidyslipidemics market is the move towards more aggressive therapy (ie multiple agents; higher doses; prolonged treatment; broader use etc). Atorvastatin (Lipitor), which has ...

When added to low-dose atorvastatin a much-discussed new monoclonal antibody to PCSK9 significantly lowers cholesterol more effectively than atorvastatin alone, according to a phase 2 study published ...

Greater Drop in LDL Seen With Atorvastatin + PCSK9 Antibody Addition of the fully human serum proprotein convertase subtilisin/kexin 9 monoclonal antibody, SAR236553, to atorvastatin is associated ...

NEW ORLEANS, LA—Hospitalizations for congestive heart failure (CHF) occurred more frequently among patients with lower baseline and 1-year estimated glomerular filtration rates (eGFR), according to ...

"Atorvastatin helps; it just is not sufficient to get everyone to target by itself." Ballantyne says increasing the dose of a statin isn't always effective. In the current study, he says, "the ...

Over 141,000 bottles of cholesterol medication have been recalled due to “failed dissolution specifications,” suggesting that ...

Pfizer will resume DTC advertising for its blockbuster statin drug, Lipitor (atorvastatin calcium)–but this time the pitchman isn’t so famous. Pfizer took heat from federal regulators and the media ...

Ezetimibe/simvastatin: 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg. Atorvastatin: 10 mg, 20 mg, 40 mg, and 80 mg. The primary end point of the study was the percent change from baseline to the end of ...

It is now widely accepted that high LDL cholesterol is a risk factor for heart disease. Furthermore, landmark studies such as the Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) ...

Please provide your email address to receive an email when new articles are posted on . New findings from the SPARCL trial showed that patients with prior stroke or transient ischemic attack ...